cessing of interleukin-1␤.
Introduction C, camptothecin, CP, or VP-16 induced caspase protease activities, as measured by cleavage of peptide substrates.
The treatment of cells with chemotherapeutic agents results in
Treatment of these cells with Ara-C also induced the procellular damage which, depending on the type of drug used, cessing of inactive procaspase-3 to an active form. 33 With can be nucleic acid damage, disruption of a metabolic prorespect to protease inhibitors, early studies demonstrated that cess, or disruption of the molecular architecture of the cell.
camptothecin-induced HL-60 apoptosis could be prevented Upon recognizing that it has been damaged, a cell may by N-tosyl-L-phenylalanylchloromethyl ketone or N-tosyl-Lattempt to repair itself. Alternatively, the drug-damaged cell lysylchloromethyl ketone. 34 Subsequent investigations have can initiate events leading to its own death via apoptosis. [1] [2] [3] [4] [5] shown that the caspase inhibitor acetyl-YVAD-chloromethyl Apoptosis is an active form of cell suicide that is characterized ketone (Ac-YVAD-CMK) inhibits the kinetics of cell death and by cell shrinkage, membrane blebbing, chromatin conden-DNA fragmentation in CP-treated malignant glioma cells 35 or sation, and DNA fragmentation. [6] [7] [8] Although these hallmark VP-16-treated HL-60 cells, 36 and benzyloxycarbonyl-VADfeatures are commonly observed in drug-induced apoptosis, fluoromethyl ketone (Z-VAD-FMK) inhibits the rate of cell relatively little is known about the signaling pathways which death in VP-16-treated THP.1 human monocytic cells. 37 are initiated in response to cellular damage. The components Studies using peptide inhibitors have examined the kinetics of these unknown pathways represent potential targets for of drug-induced apoptosis over only relatively short time novel therapies. frames. We have studied both the short-and long-term conseStudies from other systems have demonstrated that proquences of constitutive downmodulation of caspase activities teases in the caspase (or interleukin-1␤ converting enzyme using Jurkat human leukemic cells which overexpress CrmA (ICE)) protease family 9 are important mediators of apoptosis. In protein.
We report that CrmA overexpression blocks drugCaenorhabiditis elegans, mutations in the ced-3 gene abrogate induced cleavage of PARP and lamin B, as well as processing normal apoptosis during development. 10 Cloning of the cedof procaspase-3 to an active form. In addition, CrmA over-3 gene revealed that the CED-3 protein is closely related to expression significantly enhances the survival of cells followcaspase-1 (or ICE), a mammalian protease involved in the proing treatment with either Ara-C, CP, VP-16 or DOX. These findings support a role for CrmA-sensitive caspases in apoptosis induced by chemotherapy drugs with different Bcl-2 determined using a protein assay kit from Bio-Rad (Hercules, CA, USA). Protein samples were electrophoresed on 12.5%
The CrmA protein encoded by cowpox virus is a direct and SDS/PAGE gels, transferred to nitrocellulose and probed with specific inhibitor of caspase proteases. [17] [18] [19] 24 Overexpression appropriate antibodies.
of CrmA has been shown to inhibit apoptosis induced by Fas stimulation, [21] [22] [23] [24] Flasks were then placed at 37°C and incubated for 3 (Ara-C, apoptosis, 41-46 and can also inhibit apoptosis induced by exogenous expression of caspases.
14, 47 The CrmA and Bcl-2 VP-16, DOX) or 8 (CP) h. Following incubation with drug, cells were pelleted, washed once with PBS, resuspended in proteins were overexpressed in Jurkat cells as epitope-tagged proteins, 38 with the 11-amino acid KT3 epitope from SV40 T 8 ml of drug-free media, and placed at 37°C. Resuspension of the cells in drug-free media was defined as T = 0. At various antigen 48 fused to the carboxyl termini of the proteins. Figure 1 is an anti-KT3 immunoblot of lysates from two distimepoints thereafter, aliquots of the cells were removed and the percentage of cells remaining viable was determined by tinct clones of vector-transfected control cells (Vector), one clone of Bcl-2-expressing cells (Bcl-2), and two distinct clones trypan blue exclusion. For each data point a minimum of 100 cells was examined. In further analyses, the density of viable of CrmA-expressing cells (CrmA). Appropriately sized CrmA-KT3 (40 kDa) and Bcl-2-KT3 (29 kDa) fusion proteins were cells per ml of media (cell number) was determined by cell counting.
detected in the expected clones.
24 kDa fragments during apoptosis induced by drug treatment, 30 Fas activation, 24, 25 or cell confluency. 32 In the cases of Fas activation and cell confluency, cleavage of PARP has been shown to be mediated by a caspase protease. For our experiments, cells were treated with 20 M VP-16 for 6 h, followed by preparation of cytosolic extracts. The extracts were then assayed for their ability to cleave in vitro translated 35 S-PARP into characteristic fragments of 85 and 24 kDa. As shown in Figure 2 , extracts from Vector cells efficiently cleaved 35 S-PARP protein (lanes 2 and 4). This cleavage was drug-specific, since treatment of cells with DMSO, the drug diluent, had little effect (lanes 1 and 3) . In contrast to Vector cells, almost no cleavage activity was detected in CrmA or Bcl-2 cells (lanes 5-10). Given the known specificity of CrmA for inhibiting caspase proteases, [17] [18] [19] the findings presented in Figure 2 demonstrate two points: (1) caspase proteases are responsible for PARP cleavage activities in drug-treated Jurkat cells, and (2) our epitope-tagged CrmA protein efficiently blocked drug-induced caspase activities.
CrmA inhibits drug-induced intracellular cleavage of PARP and lamin B, and processing of procaspase-3
To determine whether CrmA expression could inhibit druginduced caspase activities in intact cells, we used Western significantly inhibited the drug-induced cleavage of PARP. In the case of VP-16-treated cells, Bcl-2 was more efficient than CrmA at inhibiting PARP cleavage.
Dose-response curves of Vector control cells
To determine appropriate drug concentrations to be used in subsequent experiments, dose response curves were generated using the two Vector cell lines. Cells were transiently exposed to drug (diluted into the media from 1000× stocks) for 3 h, followed by washing in PBS and replating into drugfree media. Percent viabilities were then determined 48 h after drug removal. Exposure of cells to the drug diluents DMSO or PBS was found to have no effect on cell viabilities. Based on the dose-response curves we obtained (data not shown), drug concentrations for subsequent experiments were chosen which would result in greater than 90% Vector cell death after 48 h. Specifically, Ara-C was used at 20 M, CP at 10 M, VP-16 at 20 M and DOX at 1 M.
Although Ara-C, VP-16 and DOX maintained their activities when stored as stock solutions, stocks of CP exhibited some decline in activity following prolonged (weeks) storage. Therefore, in experiments performed at later times ( Figure 5 ), exposure of Vector cells to 10 M CP resulted in somewhat less than 90% cell death.
CrmA expression inhibits drug-induced PARP cleavage from the drug-treated cell lines. PARP is cleaved to 85 and
Figure 4
Cells were plated and treated as described in Figure 3 . Immunoblots were probed with a monoclonal antibody against caspase-3 (a) or caspase-2 (b). The locations of procaspase-3 and procaspase-2 are indicated. Like PARP protein, lamin B is known to be cleaved by a CrmA expression inhibits drug-induced cell death caspase protease during apoptosis. The cleavage of lamin B precedes the fragmentation of genomic DNA to oligonucleoTo assess the chemosensitivities of the transfected cell lines, cells were transiently exposed to 20 M Ara-C, 10 M CP, somal-length fragments, 49 and appears to be mediated by a caspase protease that is distinct from the PARP cleavage 20 M VP-16, or 1 M DOX, then washed in PBS and replated into drug-free media. At various times thereafter, cell enzyme. 50 Lamin B cleavage results in the appearance of a 28 kDa fragment, using the anti-lamin B monoclonal antibody viabilities were determined by trypan blue exclusion. As shown in Figure 5 , expression of CrmA, like Bcl-2, signifiwe employed (see Materials and methods). cell death by the tetrapeptide Ac-YVAD-CMK in CP-treated melanoma cells 35 or VP-16-treated HL-60 cells, 36 and inhiIn Figure 4 we investigated whether CrmA expression could inhibit drug-induced processing and activation of specific casbition of cell death by Z-VAD-FMK in VP-16-treated THP.1 cells. 37 pase proteases. Caspase proteases are initially synthesized as inactive precursors. During apoptosis, proteolytic processing The survival advantage afforded by CrmA was sometimes equal to that provided by Bcl-2 (in the cases of Ara-C and CP), of the inactive precursor protein to smaller molecular weight forms results in the activation of enzyme activity. Thus, actiand sometimes less (VP-16 and DOX). In numerous studies, Bcl-2 has been shown to be a potent inhibitor of drug-induced vation of caspases can be assessed using Western blotting, looking for the disappearance of the 'pro' form of the molapoptosis. [41] [42] [43] [44] [45] [46] Bcl-2 also inhibits, by an unknown mechanism, the ability of caspase proteases to promote cell ecule, or appearance of the 'active' forms. In Figure 4 we examined drug-induced disappearance of the precursor form death. 14, 47 Since Bcl-2 was expressed at lower levels than CrmA in the transfected cell lines (Figure 1 ), it appears that of caspase-3 (a), a 32 kDa protein. 24, 32 As shown, treatment of Vector cells with Ara-C or VP-16 resulted in the disappearBcl-2 is more efficient than CrmA at blocking drug-induced apoptosis. This may be due to more efficient inhibition of casance of the 32 kDa procaspase-3 protein (lanes 4 and 7) . By contrast, the levels of procaspase-2 (ICH-1 L ) 47 were unaffected pase activities by Bcl-2. As described for Figure 3 , Bcl-2 is more efficient than CrmA at preventing PARP cleavage in VPby treatment with either drug (b). These results are consistent with those of Datta et al, 33 who demonstrated processing of 16-treated cells, and lamin B cleavage in Ara-C-or VP-16-treated cells. CrmA is reported by some to be a potent inhibiprocaspase-3, but not procaspase-2, in Ara-C-treated U-937 human myeloid leukemia cells. In our experiments, tor of caspase-1 (ICE), but a less potent inhibitor of caspase-3 (CPP32) and caspase-2 (ICH-1). 19, 25, 32, 37 Perhaps the reduced Discussion ability of CrmA, relative to Bcl-2, to inhibit DOX-and VP-16-induced cell death is a reflection of the specific caspases The molecular signaling pathways which are initiated in activated by these drugs. Alternatively, Bcl-2 may have other response to chemotherapy-induced cellular damage, and lead anti-apoptotic activities which are independent of caspase to the eventual apoptotic death of the cell, are largely undeproteases.
fined. The elucidation of these pathways may reveal promising new targets for anti-cancer therapies, and should contribute to our understanding of additional potential mechanisms of drug resistance. In our studies, we have shown that
Recovery and repopulation of drug-treated cells expression of CrmA protein in human T leukemic cells results in constitutive downmodulation of drug-induced caspase protease activities, as demonstrated by inhibition of PARP and Since studies using tetrapeptide inhibitors have focused primarily on the short-term effects of these inhibitors on the kinlamin B cleavage, and inhibition of procaspase-3 processing. Importantly, downmodulation of caspase activities culminated etics of cell death, we also examined the long-term consequences of caspase protease inhibition by looking at the in enhanced chemoresistance of the Jurkat leukemic cells.
Thus, these studies demonstrate that the activation of CrmArecovery of the drug-treated cells. Cells from the experiments depicted in Figure 5 were therefore maintained in drug-free sensitive caspase proteases represents a key step(s) in druginduced apoptotic signaling in the Jurkat cell line. Moreover, media for several days to weeks following removal of drug. The density of viable cells per ml was then determined at variit is important to note that CrmA expression led to enhanced resistance to multiple types of chemotherapy drugs, including ous timepoints by cell counting. Figure 6 shows that cell lines expressing CrmA or Bcl-2 eventually recovered and repopuan inhibitor of DNA synthesis (Ara-C), a DNA damaging agent (CP), a topoisomerase II inhibitor (VP-16), and a free radical lated following exposure to Ara-C, CP or VP-16. By contrast, little or no recovery was seen in Vector cells during the same generator/DNA damaging agent (DOX). This suggests that the biochemical pathways initiated by different forms of cellular time frames. No cell lines were observed to recover from DOX exposure. The differences in recoveries between Vector cells damage share at least some common signaling components, namely caspase proteases. and CrmA or Bcl-2 cells cannot be explained by differences in proliferation rates, as expression of CrmA or Bcl-2 has little
The importance of caspases in other forms of apoptosis has been more clearly defined. For example, Fas-dependent effect on cell growth (data not shown). Thus, constitutive inhibition of caspase proteases confers a selective recovery advanapoptosis is severely deficient in mice with a disrupted caspase-1 (ICE) gene. 51 Also, overexpression of CrmA in cells tage for cell populations exposed to Ara-C, CP or VP-16. The basis for this advantage remains unknown, but may reflect a sensitive to Fas activation, or incubation with tetrapeptide inhibitors of caspases, inhibits Fas-mediated cell death. [21] [22] [23] [24] [25] [26] [27] [28] greater number of viable cells remaining in the population following transient exposure to drug. The use of tetrapeptide inhibitors specific for different mem-
Figure 6
Cells exposed to drugs in Figure 5 were washed, replated in drug-free media and then monitored for long-term recovery. At varying timepoints after drug removal, the density of viable cells per ml of media was determined by counting. Data points represent the mean of triplicate samples and error bars the standard deviations. Experiments were repeated several times, with similar results each time.
bers of the caspase protease family has revealed that Fas actiapoptosis induced by anti-Fas antibodies. 52,53 These findings suggest that DOX-induced apoptosis may involve Fas vation generates a cascade of different proteases, with caspase-1 (ICE) being activated relatively early and caspase-3 ligand/Fas-dependent pathways. Whether Fas ligand is induced or Fas becomes activated in response to other chemo-(CPP32) relatively late. 26 Less is known about the role of caspases in drug-induced therapeutic agents remains to be determined. It is possible though, that drug-induced Fas activation may represent a apoptosis or drug resistance. Datta et al, 33 employing peptide substrates, have shown that caspase activities are induced in pathway leading to the activation of caspase proteases. Finally, it is important to note that a considerable problem U-937 myeloid leukemic cells following treatment with Ara-C, camptothecin, CP or VP-16. Other laboratories have found in clinical oncology is the recurrence of tumors following treatment with chemotherapy. In many instances, the molecuthat peptide inhibitors of caspase proteases can slow the kinetics of drug-induced cell death. For example, Ac-YVAD-CMK lar basis for the development of drug resistance is unknown. In cell culture, studies using tetrapeptide inhibitors have inhibits DNA fragmentation and the kinetics of apoptosis in CP-treated malignant glioma cells 35 or VP-16-treated HL-60 examined only the short-term consequences of inhibiting caspase proteases in drug-treated cells. By achieving constitutive cells, 36 and Z-VAD-FMK inhibits the rate of cell death in VP-16-treated THP.1 cells. 37 Our results using CrmA-expressing downmodulation of caspase activities in Jurkat cells through expression of CrmA, we have been able to study the longcells are consistent with these findings, and demonstrate that inhibition of CrmA-sensitive caspases confers enhanced celluterm recovery of cells transiently exposed to drugs. Our findings show that CrmA-expressing cells eventually recovered lar resistance to multiple different chemotherapy drugs.
Interestingly, in the case of U-937 myeloid leukemic cells, from transient exposure to Ara-C, CP, or VP-16, repopulating the culture flask. Vector control cells did not recover during Datta et al 33 found that expression of CrmA protein failed to inhibit Ara-C-and VP-16-induced DNA fragmentation or Arathe same time frames. Therefore, given the apparent role of caspase proteases in drug-induced apoptosis, and the C-induced cleavage of peptide substrates, PARP protein, or PKC protein. In addition, CrmA also failed to prevent Ara-Cobserved recovery of CrmA-expressing cells, it is intriguing to ask whether downmodulation of caspase proteases may induced processing of procaspase-3. By contrast, we have found that expression of CrmA in Jurkat T leukemic cells sigexplain certain forms of drug resistance or tumor recurrence. Further studies using patient samples will be needed to nificantly inhibits Ara-C-and VP-16-induced DNA fragmentation, cleavage of PARP and lamin B, and processing of proaddress these possibilities. caspase-3. These different results suggest that unique caspase proteases may be activated in different leukemic cell types. In U-937 cells the activated caspases are CrmA-insensitive, Acknowledgements while in Jurkat cells they are CrmA-sensitive.
With respect to the mechanism of drug-induced caspase activation, Friesen et al 52 
